| First Author | Kaneko J | Year | 2017 |
| Journal | Sci Rep | Volume | 7 |
| Issue | 1 | Pages | 12571 |
| PubMed ID | 28974740 | Mgi Jnum | J:255452 |
| Mgi Id | MGI:6109330 | Doi | 10.1038/s41598-017-12785-7 |
| Citation | Kaneko J, et al. (2017) Anserine (beta-alanyl-3-methyl-L-histidine) improves neurovascular-unit dysfunction and spatial memory in aged AbetaPPswe/PSEN1dE9 Alzheimer's-model mice. Sci Rep 7(1):12571 |
| abstractText | Anserine/carnosine supplementation improves cerebral blood flow and verbal episodic memory in elderly people, as we previously reported. Anserine''s buffering activity is superior to that of carnosine at neutral pH. In human sera, carnosine but not anserine is rapidly cleaved by carnosinase, limiting its effectiveness. This study examined the effects of anserine on AbetaPPswe/PSEN1dE9 Alzheimer''s disease (AD) model mice over 18-months old, an age at which these mice exhibit detectable memory deficits. We found that 8 weeks of anserine treatment completely recovered the memory deficits, improved pericyte coverage on endothelial cells in the brain, and diminished chronic glial neuroinflammatory reactions in these mice. These results suggest that anserine (beta-alanyl-3-methyl-L-histidine) supplementation improved memory functions in AD-model mice by exerting a protective effect on the neurovascular units, which are composed of endothelial cells, pericytes, and supporting glial cells. |
